Sandoz Loses Citizen Petition On Carve Outs - Good News For Generics
For years brand name companies have tried to block generics from coming on the market if their labeling carved out an indication still under patent protection. In a rare move, Sandoz has made the same argument against fellow generic manufacturers
You may also be interested in...
FDA and the generics industry are cautiously optimistic that reforms included in the FDA Amendments Act of 2007 will reduce the approval delays that generics have experienced due to citizen petitions
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials